Zevra Therapeutics Approaches Key FDA Review and PDUFA Date

Zevra Therapeutics (ZVRA) has shared an update.

Zevra Therapeutics has announced an upcoming FDA review with the Genetic Metabolic Diseases Advisory Committee to discuss the New Drug Application for arimoclomol, a potential treatment for Niemann-Pick disease type C. Slated for August 2, 2024, this key meeting precedes the drug’s PDUFA action date on September 21, 2024. The company’s forward-looking statements, while based on current plans, highlight that actual results may vary due to various risks and uncertainties.

For an in-depth examination of ZVRA stock, go to TipRanks’ Stock Analysis page.